O N C O L O G Y & H E M AT O L O G Y

I N N O VAT I O N

PRA leads the industry in advancing evidence-based approaches for thesuccessful start-up and conduct of clinical trials. Leveraging evidence-based technology, we target the appropriate geographic areas for oncology prevalence and identifya targeted list of oncology/hematology investigators with the highest likelihood of accrual.

Approximately 75% of our medical directors have expertise in oncology/hematology. Manyof our global project management and clinical operations team members are experienced in these therapeutic areas, complementing an average of 10+ years of study experience.

E X P E R T I S E

O N C O L O G Y & H E M AT O L O G Y

As a recognized leader conducting complex, global oncology/hematology trials, PRA was involved in the trials that led to the approval of 19 important drugs. During the last 5 years, we have participated in 310+ oncology/hematology clinical projects globally in every phase and virtually every indication, including supportive care.

* OVER THE PAST 5 YEARS

E X P E R I E N C E

No OF CLINICAL SITES *

14,900+

No OF CLINICAL STUDIES a

310+

No OF APPROVED DRUGS

19

No OF CLINICAL PATIENTS *

58,400+

90+ CANCER IMMUNOTHERAPYSTUDIES

4,000+ CANCER IMMUNOTHERAPYCLINICAL SITES

20.900+CANCER IMMUNOTHERAPYPATIENTS

LEVERAGING SECONDARY

HEALTH DATA

FOR DECISION SUPPORT

IN THE DESIGN AND

EXECUTION OF

CLINICAL RESEARCH

STUDIES

Natural History of DiseasePatient ProfilingKOL IdentificationRapid Online AssessmentSite List DevelopmentInvestigator IdentificationInvestigator Grant AnalysisProject Team DevelopmentCountry SelectionRecruitment ProjectionsSite Volume AnalysisPipeline AnalysisCompetitive Landscape

“Our global footprint in traditional markets – as well as emerging markets – allows us to enroll patients rapidly in oncology and hematology trials. This enables us to bring our clients’ products to market in a cost-e�ective way while optimizing time and money during the drug development process.”

DR UTE BERGER, MDSenior Vice President - Medical & Scientific Affairs,Pharmacovigilance & Patient Safety

MEDICAL DIRECTORS

=10%

CRAs PROJECT DIRECTORS AND MANAGERS

CLINICAL TEAM MANAGERS

75 85 80 85

WITH ONCOLOGY/HEMATOLOGY EXPERIENCE

P R A I S I N V E S T E D I N I M M U N O - O N C O L O G Y !

We recognize how rapidly the immunotherapy space is advancing and the importance of keeping pace with developments from the experience, knowledge resource, and team training perspectives. PRA has prioritized this challenge by establishing a cross-functional expert group to position our-selves as a leading immuno-oncology partner who applies best practices, standards, and expertiseto immuno-oncology trials in multiple treatment modalities, including cellular therapies, oncolytic viruses, cancer vaccines, checkpoint inhibitors, gut microbiome, and other novel approaches. We have collated industry and PRA team expertise into a centralized repository of standards and training. This group is also charged with formalizing and streamlining best-in-class onboarding and continual training of our project teams to ensure PRA’s capabilities grow with the clinical research landscape.

I M M U N O - O N CO LO GY E X P E R I E N C E ( 5 Y E A R S )

I/O TYPE

Immune Checkpoint Inhibitors

Cancer Therapeutic Vaccines &Oncolytic Viruses

Cellular Therapy, (CAR-T, TIL,TCR, etc.)

Other Cancer Immunotherapy

TOTAL

No OF NON-CLINICAL

PROJECTS

TARGET No OF PATIENTS

TARGET No OF S ITES

No OF CLINICAL STUDIES

49

6

25

12

92

2,850

300

558

454

4,162

11,536

1,625

2,715

5,096

20,972

13

4

4

3

24

In the last 5 years, PRA has conducted 22 oncology/hematology studies targeting 600+ pediatric patients. Our primary pediatric indications are acute lymphocytic leukemia, hemophilia, and multiplesolid tumors.

PRA's global investigator network has enabled us to establish preferred access to sites that are able to accrue patients and deliver high-quality clinical trial data.

We never forget that every global oncology/hematology study is executed locally. With global offices providing services in 90+ countries, our team harnesses practical knowledge of local regulations, standards of care, and cultural customs to maximize safety and efficiency for your oncology/hematology trials.

OUR ONCOLOGY AND HEMATOLOGY EXPERTS MAKE THE COMPLEX, SIMPLE.

PRA Health Sciences conducts comprehensive phase I-IV biopharmaceutical drug development. To learn more about our solutions, please visit us at prahs.com or email us at prahealthsciences@prahs.com.

Our commitment to advance oncology clinical development is more than lip-service; today, we o�er our clients access to approximately 50 therapeutic experts in–house with experience in conducting oncology clinical trials.

To save lives, or enable people to live be�er lives, is no small thing. With every drug that we help bring to market, we not only improve the lives of the individuals who need it, but also all the lives that they touch. The ripples are countless, but the benefit is clear. With each and every trial, we’re working with our clients to change lives and to make the world a be�er place.

Our commitment to advancing oncology/hematology clinical development is more than words; today, we o�er our clients access to approximately 70 in-house therapeutic experts with experience conducting oncology/hematology clinical trials.

To save lives, or enable people to live be�er lives, is no small thing. With every drug we help bring to market, we not only improve the lives of the individuals who need it, but also all the lives that they touch. The ripples are endless, but the benefit is clear. With each and every trial, we’re working with our clients to change lives and make the world a be�er place.

PRA Health Sciences conducts comprehensive Phase I-IV biopharmaceutical drug development. To learn more about our solutions, please visit us at prahs.com or email us at prahealthsciences@prahs.com. MAY2019